Vaccines

New clinical data suggests a more convenient option for cancer patients, potentially eliminating a return trip to the clinic for a key supportive care drug.

Biotech firm Bright Minds Biosciences closes a massive $175M deal, fueling its race to develop novel drugs for epilepsy and rare neurological conditions.

Promising Phase 2 data shows a new DNA immunotherapy for advanced melanoma, delivered via a needle-free jet injector, significantly improves patient outcomes.

As part of a $23B US investment, Novartis will build a cutting-edge facility in Winter Park, cementing Florida’s role in advanced cancer treatment.

A new alliance aims to advance KFRX06, a unique Parkinson's therapy that goes beyond a single target to potentially offer a more comprehensive treatment.

Prescryptive and Ilant Health unveil a direct-to-employer model for obesity drugs, promising transparent pricing and better clinical outcomes for employers.

Akari Therapeutics is advancing a new class of cancer drugs. Its unique PH1 payload kills tumors and activates the immune system, setting up a pivotal 2026.

With promising data in hard-to-treat cancers, iOnctura's lead drug, roginolisib, is set to make waves at the top healthcare investment forum.

After a major business sale, Elutia is launching NXT-41x, an antibiotic biomatrix designed to combat the high rate of infection in breast reconstruction.

Riding a 50% revenue surge, Rhythm Pharmaceuticals faces a pivotal year with a major FDA decision and key clinical data for its rare obesity treatments.

With up to $80.8M in new funding, Curis is set to accelerate trials for emavusertib, a promising drug targeting some of the toughest blood cancers.

With the appointment of Dr. Stephen Eck, Flare Therapeutics signals a major push to advance its first-in-class cancer therapies targeting transcription factors.

Biocytogen and Acepodia are expanding their partnership to create next-gen ADCs with two targets and two warheads, aiming to defeat drug-resistant cancers.

Belgian biotech MRM Health gets the green light for a Phase 2b trial of MH002, a novel 'living drug' aimed at revolutionizing ulcerative colitis care.

As Valneva meets investors, all eyes are on its pivotal Lyme disease vaccine data, a potential game-changer for public health and the company's future.

Alessa Therapeutics’ rice-sized implant, Enolen, earns FDA Fast Track, promising a new era for prostate cancer therapy without debilitating side effects.

New research reveals a stark disconnect between clinical views and patient reality in atopic dermatitis, with millions suffering severe, overlooked impacts.

With key studies now complete, Biofrontera's light-based therapy Ameluz could soon offer a new weapon against widespread actinic keratosis and stubborn acne.

NeuroSense adds world-renowned expert Prof. Steven Arnold to its board, a major vote of confidence in its multi-target Alzheimer's drug, PrimeC.

Positive early human safety data for its lead drug and new candidates for Rett syndrome and MASH signal a pivotal year for ProQR's Axiomer technology.